Study could lead way to personalized medicine for heart disease | Montreal Gazette
Dalcetrapib - an overview | ScienceDirect Topics
Cholesterol Ester Transfer Protein Inhibitor - an overview | ScienceDirect Topics
Roche to Develop Companion Diagnostic Test for Dalcetrapi - Elets eHealth
Dalcetrapib
Roche Abandons Dalcetrapib Trial
Roche Abandons Dalcetrapib Trial
Dalcetrapib - an overview | ScienceDirect Topics
PDF) Dalcetrapib preserves CETP-induced pre-β-HDL formation in vitro, in contrast to torcetrapib and anacetrapib | Evelyne Chaput - Academia.edu
Roche stops heart drug trial as data disappoints | Fox News
Roche Abandons Dalcetrapib Trial
PDF) Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats | Eric Niesor - Academia.edu
Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib | Clinical Pharmacokinetics
Roche Sees Big Potential in New Drugs - WSJ
PDF) Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
PDF) Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Herzmedikament Dalcetrapib: Roche stellt Entwicklung ein - DER SPIEGEL
Pharma – Roche stoppe un médicament, le titre dévisse | 24 heures
PDF) Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib | Robert Hegele - Academia.edu
PDF) Cholesteryl ester transfer protein inhibitors for dyslipidemia: Focus on dalcetrapib
Dalcetrapib
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. - Abstract - Europe PMC
Roche Abandons Dalcetrapib Trial
Dalcetrapib - Wikipedia
Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects | Clinical Drug Investigation
PDF) Safety and Tolerability of Dalcetrapib | Brendan Buckley and David Kallend - Academia.edu
62032-x.fp.png "STATIN–INDUCED DECREASE IN ABCA1 EXPRESSION VIA MIR33 INDUCTION MAY COUNTERACT CHOLESTEROL EFFLUX BY HIGH–DENSITY LIPOPROTEINS RAISED WITH THE CHOLESTERYL ESTER TRANSFER PROTEIN MODULATOR DALCETRAPIB | Journal of the American College of Cardiology")
STATIN–INDUCED DECREASE IN ABCA1 EXPRESSION VIA MIR33 INDUCTION MAY COUNTERACT CHOLESTEROL EFFLUX BY HIGH–DENSITY LIPOPROTEINS RAISED WITH THE CHOLESTERYL ESTER TRANSFER PROTEIN MODULATOR DALCETRAPIB | Journal of the American College of Cardiology
Dalcetrapib (JTT-705) | CETP Inhibitor | MedChemExpress
